Formulation analyses of high-volume prescription drugs
Source abstract
Abstract
A collection of 65 formulated tablets and capsules were analyzed for phase composition by full pattern matching powder diffraction methods. The collection contained 32 of the top 200 prescription drugs sold in 2016 as well as many high-volume prescriptions and over the counter drugs from prior years. The study was used to evaluate new methods of analysis as well as the efficacy of programs designed to collect references on high volume excipients and pharmaceuticals for inclusion in the Powder Diffraction File ™ . The use of full pattern matching methods as well as reference pattern additions of many common excipients enabled major phase excipient identification in all formulations. This included identification of crystalline, nanocrystalline, and amorphous ingredients because full pattern matching involved the use of characteristic coherent and incoherent scatter. Oftentimes identification of the major excipients significantly aided the clean identification of the active pharmaceutical ingredients (APIs) and their polymorphic form, even at low concentrations (1–10 wt. %). Overall 93% of the APIs were identified, most through a PDF ® material reference, but also through patent cross-referencing and similarity analysis comparisons.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: X-ray Diffraction in Crystallography · Crystallization and Solubility Studies · Crystallography and molecular interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. 10.1017/S088571561600059210.1017/S0885715616000592 ↗
2. Whitfield · 2019 · 20010.1107/97809553602060000945 ↗
3. 10.1002/jps.2220410.1002/jps.22204 ↗
4. 10.1154/1.213530910.1154/1.2135309 ↗
5. Rowe · 2009 · 728
6. 10.1039/c2cp43378h10.1039/c2cp43378h ↗
7. 10.1017/S088571561700112910.1017/S0885715617001129 ↗
8. 10.1021/ed100380610.1021/ed1003806 ↗
9. Madsen · 2019 · 34410.1107/97809553602060000954 ↗
10. Kaduk · 2019 · 30410.1107/97809553602060000952 ↗
11. International Centre for Diffraction Data (2017). PDF-4+2018 (Database), edited by Dr. Soorya Kabekkodu, International Centre for Diffraction Data, Newtown Square, PA, USA.
12. 10.1017/S088571561400013X10.1017/S088571561400013X ↗
13. 10.1017/S088571561900023X10.1017/S088571561900023X ↗
14. 10.1017/S088571561700028810.1017/S0885715617000288 ↗
15. Fawcett T. G. , Kabekkodu S. N. , Zhong K. , Gindhart A. M. , Blanton J. R. , and Blanton T. N. (2015b). Analyzing amorphous and nanocrystalline materials by full pattern analysis. presented at PPXRD-13, 18–21 May 2015, Bad Herranalb, Germany. Full presentation available for free download at http://www.icdd.com/assets/ppxrd/presentations/13/PPXRD-13-Fawcett.pdf
16. 10.1017/S088571561200093010.1017/S0885715612000930 ↗
17. 10.1154/1.220495810.1154/1.2204958 ↗
18. Formulation Analysis of Off-the-Shelf Pharmaceuticals
19. Blanton T. N. (2013). Eastman Kodak Co., Rochester, NY private communication, powder diffraction analyses of gelatins, includes the publication of gelatin references PDF#’s 00-064-1605, 00-064-1606 and 00-064-1607.
20. Billinge S. J. L. (2011). Total Scattering Pair Distribution Functions (TSPDF) for Fingerprinting Amorphous Pharmaceuticals. presented at PPXRD-10, 16-19 May 2011, Lyon, France. Full presentation available for free download at http://www.icdd.com/assets/ppxrd/presentations/10/PPXRD-10_Simon_Billinge.pdf.
21. 10.1154/1.235835910.1154/1.2358359 ↗
22. Kaduk J. A. , Wheatley A. M. , Gindhart A. M. , and Blanton T. N. (2018). “Crystal structures of large volume commercial pharmaceuticals,” poster presentation ICDD Spring Meeting, 2018, Newtown Square, PA, USA.
23. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
24. 10.1107/S002188980401374310.1107/S0021889804013743 ↗
25. “Simulation tools and references for the analysis of nanomaterials
26. Hu X. , Fang H. , Feng J. , and Jianyue G. (2012). “ Novel crystalline form of benazepril hydrochloride and preparation method of crystalline form,” patent CN103012267B, assigned to Zhejiang University.
27. Murakami N. (2006). ” Crystalline form of 1- (delta-D-glucopyranosyl) −4 -methyl- 3- [5- (4 –fluorophenyl) −2-thienylmethyl] benzene hemihydrate,” patent CN101573368B assigned to Mitsubishi Tanabe Pharmaceutical Co., Ltd.
28. Gates-Rector S. , Blanton T. N. , Gindhart A. M. , and Kaduk J. A. (2018). Crystal Structure Determination and Phase Identification of Pharmaceutical Material(s) Using Powder Diffraction Techniques. Poster presentation ICDD Spring Meeting, 2018, Newtown Square, PA, USA.
29. 10.1016/j.jpba.2015.01.00510.1016/j.jpba.2015.01.005 ↗
30. International Pharmaceutical Excipient Council (IPEC) America (2018). Most commonly used excipients in U.S.-manufactured drug products . http://ipecamericas.org/what-ipec-americas/faqs
31. 10.1154/1.291855010.1154/1.2918550 ↗
32. Fawcett T. G. , Kabekkodu S. N. , Gates-Rector S. , Gindhart A. M. , Blanton J. R. , and Blanton T. N. (2016). The Analysis of Non-Crystalline Materials in Pharmaceutical Formulations. presented at PPXRD-14, Sanibel Harbor Marriott, Fort Myers, Florida, USA.
33. International Centre for Diffraction Data (2014a). “Technical Bulletin, PDF-4/Organics,” published by the ICDD. Nano material examples for apatite and Lipitor given in the case histories. Available for free download at http://www.icdd.com//wp-content/uploads/2018/03/PDF-4_Organics_Technical_Bulletin.pdf
34. United States, Code of Federal Regulations, Title 21, Vol 4, 21CFR201.10 (2017).“Food and Drugs, Subchapter C – Drugs General, Part 201 – Labelling. ”
35. International Centre for Diffraction Data (2014b). “Technical Bulletin, Search and Identify with SIeve/SIeve+,” published by the ICDD. Available for free download at http://www.icdd.com//wp-content/uploads/2018/03/SIeve-Technical-Bulletin.pdf
36. 10.1107/S002188980400039110.1107/S0021889804000391 ↗
37. Aher U. P. , Tarur V. R. , Sathe D. G. , Naidu A. V. , and Sawant K. D. (2007). “Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof,” US Patent 7,186,842.